小结
定义
病史和查体
诊断性检查
治疗流程
贡献者
作者 查看所有
Clinical Professor
Departments of Medicine, Pediatrics and Oncology
Cumming School of Medicine
University of Calgary
Calgary
Canada
利益冲突披露
M-CP is on advisory boards for Biogen-Idec, CSL-Behring, Novo Nordisk, Pfizer, Bayer, Baxalta, and Octapharma , he has been sponsored as a speaker by Pfizer, Bayer, and Novo Nordisk , and has done consulting work for Spark Therapeutic Inc. M-CP has received grant funding from CSL-Behring and Bayer, and has participated in sponsored research for CSL-Behring. M-CP is an unpaid volunteer for the World Federation of Hemophilia.Clinical Assistant Professor
Department of Medicine
Cumming School of Medicine
University of Calgary
Calgary
Canada
利益冲突披露
AL has received fellowship training funding from the Bayer Hemophilia Award program. Her research project received peer-reviewed grant support from Canadian Hemophilia Society and Pfizer's Care Until Cure award. AK received investigator-initated research funding from Biogen. She has also served on an advisory board for Pfizer, and received travel funds from Baxalta.Professor Poon and Dr Lee would like to gratefully acknowledge Dr Nigel S. Key, Dr Paul Giangrande, Dr Nidra I. Rodriguez, and Dr W. Keith Hoots, the previous contributors to this topic. NSK has undertaken paid consultancy for Baxter Biosciences, Novo Nordisk, CSL Behring, and Bayer. He has received grant funding from Baxter. PG has undertaken paid consultancy and/or received lecture fees from the following companies involved in haemophilia care: Bayer, CSL Behring, NovoNordisk, Pfizer/ BPL, Octapharma, Biogen Idec, and Biotest. NSK, NIR, and WKH are authors of reference(s) cited in this monograph.
同行评议专家 查看所有
The Mary Weinfeld Professor of Clinical Research in Hemophilia
Mount Sinai School of Medicine
New York
NY
利益冲突披露
LA declares that he has no competing interests.Associate Professor of Medicine
Innsbruck Medical University
Innsbruck
Austria
利益冲突披露
CP declares that he has no competing interests.
使用此内容应接受我们的免责声明。
